During the six months ended June 30, 2023, we had cash provided by financing activities of $0.1 million, consisting of proceeds from the participation in the employee stock purchase plan. During the six months ended June 30, 2022, we had cash provided by financing activities of $0.2 million consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan. | --- | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|- ...

• the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators; • the extent of any required post-marketing approval commitments to applicable regulatory authorities; • development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch; General and administrative Other income was $0.7 million for the three mon ...

• our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available; • our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals; Table of Contents PART I Approved targeted therapies, such as kinase inhibitors, have transformed the treatment of cancers and demonstrated a significant benefi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBE ...

| --- | --- | --- | --- | |-----------------------------------------|-----------|-------|------------| | | | | | | | | | | | Black Diamond Therapeutics, Inc. | | | | | | | | | | | | | | | Pioneering the Development of MasterKey | Therapies | | | | | | | APRIL 2022 | 1 Important Notice and Disclaimers 2 This presentation contains "forward-looking statements" of Black Diamond Therapeutics, Inc. ("Black Diamond," "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These f ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 BDTX The Nasdaq Global Select Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ...

Table of Contents ___________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE N ...

| --- | --- | --- | |-----------------------------------------|-----------|--------------| | | | | | | | | | Black Diamond Therapeutics, Inc. | | | | | | | | | | | | Pioneering the Development of MasterKey | Therapies | | | | | JANUARY 2022 | 1 Important Notice and Disclaimers 2 This presentation contains "forward-looking statements" of Black Diamond Therapeutics, Inc. ("Black Diamond," "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statement ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________________________________________ FORM 10-Q ___________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _ TO _ COMMISSION FILE NUMBER 001-38501 ___________________ ...